Physician profile
Amanda Ayers
NPI 1982161782
$6,337.02
in general payments reported to CMS, 2019-2025
23 companies · $881 in 2025
The $881 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.33 · 2022: $804 · 2023: $2,493 · 2024: $2,145 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,331.93 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,339.85 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,205.18 | 2022-2025 | |
| Amgen INC. | $1,155.76 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $441.81 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $413.91 | 2022-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $356.68 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $310.28 | 2022-2025 | |
| Lilly USA, LLC | $306.54 | 2022-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $219.66 | 2023-2025 | Benlysta, Nucala |
| Janssen Scientific Affairs, LLC | $91.30 | 2023 | Tremfya, Remicade, Stelara |
| Aurinia Pharma U.S., INC. | $82.60 | 2024-2025 | Lupkynis |
| Janssen Pharmaceuticals, INC | $81.59 | 2025 | Tremfya |
| Pfizer INC. | $74.48 | 2022-2023 | |
| Horizon Therapeutics Plc | $60.53 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.94 | 2023-2024 | Ofev |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $29.65 | 2024 | |
| Alexion Pharmaceuticals, INC. | $29.12 | 2024 | Strensiq |
| Astrazeneca Pharmaceuticals Lp | $20.61 | 2022 | |
| Sandoz INC. | $19.20 | 2024 | Hyrimoz |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
| Kiniksa Pharmaceuticals, Ltd. | $18.47 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $15.70 | 2024 | Arcalyst |
| Jazz Pharmaceuticals INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.